Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 5/20 | 0.67 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.67 |
| ▸ | PSMB2 | P49721 | 4/20 | 0.67 |
| ▸ | LTA4H | P09960 | 11/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.63 |
| ▸ | ESR1 | P03372 | 1/20 | 0.61 |
| ▸ | PDE1A | P54750 | 1/20 | 0.61 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.61 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4708977 | 0.98 | PSMB1 (0.70) | PSMB1PSMB5PSMB2LTA4HHRH3 | |
| SCHEMBL1778223 | 0.98 | PSMB1 (0.70) | PSMB1PSMB5PSMB2LTA4HHRH3 | |
| SCHEMBL73562 | 0.91 | HRH3 (0.72) | HRH3PDE1APDE1BPDE1C | |
| SCHEMBL16358313 | 0.89 | HRH3 (0.71) | HRH3PDE1APDE1BPDE1C | |
| SCHEMBL2819407 | 0.89 | HRH3 (0.75) | HRH3PDE1APDE1BPDE1C | |
| SCHEMBL737990 | 0.89 | HRH3 (0.75) | HRH3PDE1APDE1BPDE1C | |
| SCHEMBL12834986 | 0.88 | HRH3 (0.73) | HRH3PDE1APDE1BPDE1C | |
| SCHEMBL17197058 | 0.84 | DRD3 (0.52) | PSMB1PSMB5PSMB2LTA4HHRH3 | |
| SCHEMBL3562722 | 0.84 | NPC1 (0.66) | LTA4HHRH3KDM4E | |
| SCHEMBL3578646 | 0.83 | HRH3 (0.90) | PSMB1PSMB5PSMB2LTA4HHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015187684-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| US-8618132-B2 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-12-31 | — | — | US | disclosed |
| EP-1558578-B1 | NOVEL ALKYNE COMPOUNDS HAVING AN MCH ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING THESE COMPOUNDS | BOEHRINGER INGELHEIM PHARMA (DE) | 2013-03-13 | — | — | EP | disclosed |
| US-20090069282-A1 | ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-03-12 | — | — | US | disclosed |
| US-7452911-B2 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-11-18 | — | — | US | disclosed |
| US-7329654-B2 | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-12 | — | — | US | disclosed |
| US-7105679-B2 | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | KANOJIA RAMESH M | 2006-09-12 | — | — | US | disclosed |
| US-20060074244-A1 | Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway | GELLIBERT FRANCOISE J | 2006-04-06 | — | — | US | disclosed |
| EP-1467998-B1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | ORTHO MCNEIL PHARM INC (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20060058329-A1 | Pyrazole inhibitors of the transforming growth factor | SMITHKLINE BEECHAM CORPORATION | 2006-03-16 | — | — | US | disclosed |
| US-20040259915-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | KANOJIA RAMESH M (US) | 2004-12-23 | — | — | US | disclosed |
| US-20040209865-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-10-21 | — | — | US | disclosed |
| EP-1467998-A1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2004050660-A1 | NOVEL HETEROATOM CONTAINING TETRACYCLIC DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004016606-A1 | PYRAZOLE INHIBITORS OF THE TRANSFORMING GROWTH FACTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-26 | — | — | WO | disclosed |
| WO-2004013125-A1 | PYRIDINYL SUBSTITUTED (1,2,3,)TRIAZOLES AS INHIBITORS OF THE TGF-BETA SIGNALLING PATHWAY | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-12 | — | — | WO | disclosed |
| WO-2004013134-A2 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-12 | — | — | WO | disclosed |
| WO-2004013135-A1 | 2-PHENYLPYRIDIN-4-YL DERIVATIVES AS ALK5 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-12 | — | — | WO | disclosed |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003053977-A1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058329-A1 | Pyrazole inhibitors of the transforming growth factor | SMAD3, SMAD2, TGFBR1 | PSMB1 2895/4885PSMB5 1169/4885PSMB2 2902/4885 |
| US-20040259915-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | GPER1, ESR2, FSHR | PSMB1 1278/4885PSMB5 833/4885PSMB2 1340/4885 |
| US-20090069282-A1 | ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | MCHR1, MCHR2, GPR119 | PSMB1 4465/4885PSMB5 2696/4885PSMB2 4171/4885 |
| US-20040209865-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, MCHR2, NPY1R | PSMB1 4198/4885PSMB5 2697/4885PSMB2 3792/4885 |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | GPER1, ESR2, FSHR | PSMB1 1278/4885PSMB5 833/4885PSMB2 1340/4885 |
| US-20060074244-A1 | Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway | SMAD3, TGFBR1, SMAD2 | PSMB1 2552/4885PSMB5 1534/4885PSMB2 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.